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About the OECD 
 
 
 The Organisation for Economic Co-operation and Development (OECD) is an intergovernmental 
organisation in which representatives of 34 industrialised countries in North and South America, Europe 
and the Asia and Pacific region, as well as the European Commission, meet to co-ordinate and harmonise 
policies, discuss issues of mutual concern, and work together to respond to international problems. Most of 
the OECD’s work is carried out by more than 200 specialised committees and working groups composed 
of member country delegates. Observers from several countries with special status at the OECD, and from 
interested international organisations, attend many of the OECD’s workshops and other meetings. 
Committees and working groups are served by the OECD Secretariat, located in Paris, France, which is 
organised into directorates and divisions. 
 
 The Environment, Health and Safety Division publishes free-of-charge documents in eleven 
different series: Testing and Assessment; Good Laboratory Practice and Compliance Monitoring; 
Pesticides; Biocides; Risk Management; Harmonisation of Regulatory Oversight in Biotechnology; 
Safety of Novel Foods and Feeds; Chemical Accidents; Pollutant Release and Transfer Registers; 
Emission Scenario Documents; and Safety of Manufactured Nanomaterials. More information about 
the Environment, Health and Safety Programme and EHS publications is available on the OECD’s World 
Wide Web site (http://www.oecd.org/chemicalsafety/). 
 
 
 
This publication was developed in the IOMC context. The contents do not necessarily reflect the views or 
stated policies of individual IOMC Participating Organisations. 
 
The Inter-Organisation Programme for the Sound Management of Chemicals (IOMC) was established in 
1995 following recommendations made by the 1992 UN Conference on Environment and Development to 
strengthen co-operation and increase international co-ordination in the field of chemical safety. The 
Participating Organisations are FAO, ILO, UNDP, UNEP, UNIDO, UNITAR, WHO, World Bank and 
OECD. The purpose of the IOMC is to promote co-ordination of the policies and activities pursued by the 
Participating Organisations, jointly or separately, to achieve the sound management of chemicals in 
relation to human health and the environment. 
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FOREWORD 
 This document includes the Feasibility study for minor enhancements of TG 421/422 
(Reproduction / Developmental Toxicity Screening Test) / (Combined Repeated Dose Toxicity Study 
with the Reproduction / Developmental Toxicity Screening Test) with Endocrine Disrupter-relevant 
endpoints. The objective of the project, proposed by Denmark in 2013, was to examine the feasibility 
of inclusion of sensitive endpoints for the detection of chemicals with endocrine disrupting properties 
in TGs 421/422 and to update the TGs accordingly.  
 
 The feasibility report is based on statistical analyses of the proposed additional endpoints – 
nipple retention, anogenital distance and thyroid. The statistical analyses are available as annexes to 
the report, which also includes proposals for an update of the version of TGs 421/422 published 
respectively in 1995 and 1996. 
 
 The draft feasibility report was circulated for comments to the WNT in September 2014. 
Comments received were addressed by the Lead Country, in consultation with the expert group on 
reproductive toxicity and further thyroid data analysis were conducted early 2015. The feasibility 
report was updated in February, based on this additional analysis and was approved by the WNT in 
April 2015, declassified and published under the responsibility of the Joint Meeting of the Chemicals 
Committee and the Working Party on Chemicals, Pesticides, and Biotechnology on 10 July 2015.  
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Terms of reference  
 
1. This draft report has initially been prepared by the National Food Institute, 
Technical University of Denmark. The report gives input for discussions in the OECD 
working group of experts involved in the project Feasibility study for minor enhancements of 
TG 421/422 (Reproduction/Developmental Toxicity Screening Test) /(Combined Repeated 
Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test) with 
ED-relevant endpoints. Subsequently, the draft report has been revised based on the 
discussions in this working group. 
 
AIM  
 
2. The aim of this project is to do a feasibility study for minor enhancements of TG 
421/422 (Reproduction/Developmental Toxicity Screening Test) /(Combined Repeated Dose 
Toxicity Study with the Reproduction/Developmental Toxicity Screening Test) with ED-
relevant endpoints. This review addresses scientific and technical concerns regarding 
inclusion of additional ED related endpoints in TGs 421/422. The endpoints considered 
include anogenital distance (AGD), Nipple Retention (NR), thyroid hormones and 
malformations of external reproductive organs in male offspring. For these endpoints, the 
scientific and technical questions considered include: 
• Are standardized methods available? 
• Is the sensitivity sufficient with the number of litters per group?  
• Are the endpoints of relevance for humans? 
• Are there animal welfare concerns? 
• Is the enhancement possible without changes or with only minor changes in study 
design? 
 
BACKGROUND AND EXPECTED REGULATORY NEED/DATA REQUIREMENT THAT 
WILL BE MET BY THE PROPOSED OUTCOME OF THE PROJECT 
 
3. The TGs 421/422 (Reproduction/Developmental Toxicity Screening Test) 
/(Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity 
Screening Test) provides information on adverse effects on development and reproduction 
including effects on endocrine organs and is used in various regulatory frameworks (such as 
REACH) to generate information for risk assessment of chemicals. In GD 150 (Guidance 
Document on Standardised Test Guidelines for Evaluating Chemicals for Endocrine 
Disruption) it is written: “The reproduction/developmental screening tests OECD TG 421 
and 422 are included in Level 4 as supplemental tests because they give limited but useful 
information on interaction with endocrine systems. EDs may be detected by effects on 
reproduction (gestation, gestation length, dystocia, implantation losses), genital 
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malformations in offspring, marked feminized AGD in males, changes in histopathology of 
sex organs or effects on the thyroid gland” (OECD 2012). 
 
4. However, it is recognized that these in vivo screens need to be updated in relation to 
inclusion of some sensitive effect endpoints relevant for Endocrine Disruption. In the revised 
OECD Conceptual Framework (CF) from OECD the reproduction/developmental screening 
tests TGs 421 and 422 are included in Level 4 “if enhanced” as supplemental tests because 
they provide limited but useful information on interaction with endocrine systems (OECD 
2012).  
 
5. DK has undertaken the examination of available existing data and peer review 
scientific relevant papers to make a proposal to the Validation Management Group on 
mammalian testing (VMG-mammalian) /Expert group (EG) on reproductive toxicity, on 
whether or not it is relevant to include these ED related endpoints in a proposal for revision 
of OECD TG 421 and 422.  
6. It will also be considered whether certain slight adaptions of the test designs of these 
test guidelines may be warranted to include for consideration other ED related endpoints if 
such are being suggested by the EG/VMG-mammalian for this project.  
7. The results of the project may contribute to an improved sensitivity for identification 
of developmental toxicants in mammalian species at an early stage in the regulatory testing 
schemes for industrial chemicals (e.g. REACH) as information from TGs 421/422 are already 
required in such regulatory testing schemes.  
8. If these endpoints are implemented in these TGs it will enhance the international 
harmonization of hazard assessment with regard to developmental toxicity effects (OECD 
2012).  
9. An important point is that the ability for detection of EDs can be enhanced without 
increasing the number of experimental animals used.  
10. Assessment of AGD and NR are mandatory in TG 443 and could probably easily be 
included in the TG 421/422. For the examination of NR it is, however, needed to extend the 
study period in 421/422 from PND 4 to PND 12 or13 to examine this endpoint at the optimal 
time period.  
11. The OECD TG 407 (Repeated dose 28- day oral toxicity study in rodents) has been 
updated in 2008. The assay has been validated for some endocrine endpoints but the 
sensitivity of the assay is not sufficient to identify all EATS-mediated EDs. The validation of 
the assay (OECD, 2006) showed that it identified strong and moderate EDs acting through 
the ER and AR; and EDs weakly and strongly affecting thyroid function. It was relatively 
insensitive to weak EDs acting through the ER and AR. This assay also has some optional 
endpoints such as uterine and ovary weight, changes in vaginal smears, histopathologic 
changes in mammary gland histopathology as well as serum T3, T4, TSH as well as thyroid 
weight which can be examined if there is additional concern.  
ENV/JM/MONO(2015)24 
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12. The new extended one-generation reproductive toxicity study (EOGRTS) (OECD 
TG 443) includes more endpoints sensitive to endocrine disruption than OECD TG 416 and, 
as it also uses reduced animal numbers if conducted without F2, it is expected that it will 
often replace OECD TG 416 for mammalian reproductive toxicity testing (GD 150). 
Endpoints sensitive to endocrine disruption, not specified in OECD TG 416, include 
anogenital distance at birth, areola/nipple retention, measurement of thyroid hormones and 
TSH levels. Effects on the developing nervous and immune systems are also assessed by the 
DNT and DIT cohorts. These systems may also be sensitive to endocrine influences. This test 
is also expected to have greater sensitivity than OECD TG 416 as it requires an increased 
number of pups to be examined. In summary, the new EOGRT study (OECD TG 443) is 
preferable for detecting endocrine disruption because it provides an evaluation of a number of 
endocrine endpoints in the juvenile and adult F1, which are not included in the 2-generation 
study (OECD TG 416) adopted in 2001. 
13. This review also focuses on genital malformation. In TG 443 all selected F1 animals 
are evaluated around sexual maturity and notes are taken for any abnormalities of genital 
organs, such as persistent vaginal thread, hypospadias or cleft penis. In the current TG 422 it 
is noted that each litter should be examined as soon as possible after delivery to establish the 
number and sex of pups, stillbirths, live births, runts (pups that are significantly smaller than 
corresponding control pups), and the presence of gross abnormalities.  
14. The power of the update endpoints in TG 421/422 with around 8 litters per group 
compared with the power for similar endpoints in OECD TG 443 with around 20 litters per 
group is important to consider. This has been done by conducting statistical analyses of 
existing data (cf. Appendix 1a). 
15. TG 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents) was enhanced in 
2008 with regard to inclusion of some ED relevant endpoints. However, it seems even more 
relevant to also include some ED relevant endpoints in TG 421/422 where the exposure 
periods cover some of the sensitive periods during development (pre- or early postnatal 
periods).  
16. AGD and NR have the last decades been shown to be sensitive and non-invasive 
endpoints, when investigating effects of anti-androgenic compounds administered during the 
critical periods of prenatal development (Clark et al. 1990, Gray et al. 1999, McIntyre et al. 
2000, Mylchreest et al. 1999, Hass et al. 2007).  
17. Animal studies indicate that both AGD and NR are sensitive markers for increased 
risk of malformations of the external reproductive organs (Christiansen et al. 2008, Bowman 
et al., 2003, McIntyre et al., 2002; Welsh et al 2008). Moreover, AGD and NR examinations 
have been included in the new TG 443 (Extended One-Generation Reproductive Toxicity 
Study) and in both GD 43 and GD 151 it is stated that AGD can be used for NOAEL setting 
(OECD 2008, OECD 2013).  
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Anogenital distance (AGD) 
 
Method  
18. New-born male rats have no scrotum, and the external genitalia are undeveloped, 
and only a genital tubercle is apparent for both sexes. The AGD is the distance from the anus 
to the insertion of this tubercle, the developing genital bud. The AGD is androgen dependent, 
and studies show that the AGD is normally about twice as long in male as in female rats. 
Similarly, in new-born humans the AGD measure was about two-fold greater in males than in 
females (Salazar-Martinez et al. 2004). 
19. The method for assessing AGD is already described in para 45 in TG 443, i.e.: 
45. The anogenital distance (AGD) of each pup should be measured on at least 
one occasion from PND 0 through PND 4. Pup body weight should be 
collected on the day the AGD is measured and the AGD should be normalized 
to a measure of pup size, preferably the cube root of body weight (12).  
20. Some further guidance is given in GD 34, i.e.: 
165. AGD may be influenced by the size of the animal and this should be taken 
into account when evaluating the data. The size or length of the pups is 
normally not measured (sometimes crown-rump), but body weights are 
measured. In some cases, the anogenital index, i.e., AGD divided by body 
weight, is used. However, body weights of pups may be quite variable leading 
to a large variation in the anogenital index. This could mask eventual effects 
on AGD and is therefore not recommended. Instead, the size of the animals 
should be accounted for by including a covariant. Body weight can be used, 
but this parameter is in three dimensions, while AGD is in one dimension. 
Consequently, the optimal covariate seems to be the cube root of the body 
weight (Clark, 1999). A statistically significant change in AGD that cannot be 
explained by the size of the animal indicates effects of the exposure and should 
be used for setting the NOAEL. 
21. In GD 150 it is written: “For example, feminized AGD in male offspring (observed 
in OECD TG 416 and possibly in OECD TG 421/422) may be considered as conclusive 
evidence of an endocrine disrupting effect”.  
22. Thus changes in AGD in the OECD 421/422 screening studies can be used for 
setting an NOAEL. However, if the result is not reproducible in larger, more definitive 
studies (e.g., OECD 443), the results may be overridden, depending on a case by case 
evaluation including e.g. the dose levels used in the two types of studies. 
 
Data analysis, sensitivity/power  
23. Power Simulations of Nipple Retention and Anogenital Distance of Rodents have 
been made and are referred to in appendix 1a. These power simulations can be used to 
calculate the minimum sample size required, in order to likely detect an effect of a given size 
on the endpoint (e.g. AGD). Power analysis can also be used to calculate the minimum effect 
size that is likely to be detected in a study using a given sample size. 
ENV/JM/MONO(2015)24 
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24. For continuous endpoints like AGD the statistical power for detecting significant 
effects depends on the group size, and on the coefficient of variation in the control group. The 
effect size needed for having at least 80% probability for detecting significant effects (p < 
0.05) of a given size on AGD is described in details in Appendix 1a.  
25. The results based on both the Copenhagen studies (data from Division of Toxicology 
and Risk Assessment, National Food Institute, Technical University of Denmark) and the 
non-Copenhagen studies (Data from other labs) shows that the detection of a 5% reduction in 
male AGD can be ensured only with at least 16 litters per group. The likelihood for detection 
of a 10% reduction in male AGD is very high with 8 litters per group.  
 
Human relevance 
26. In rats, both AGD and nipple retention has been shown to be highly predictive of 
adverse effects of the male reproductive system including increased incidence of 
hypospadias, testosterone decrease and altered reproductive organ weight changes (Bowman 
et al. 2003, Christiansen et al. 2008, Macleod et al. 2010, van den Driesche et al. 2011, Welsh 
et al. 2008).  
27. Anogenital distance has been shown to be associated with adverse health effects in 
humans (Bornehag et al 2014). Recent studies reported that male infants and boys with 
hypospadias or undescended testis had reduced AGD (Hsieh et al. 2012; Hsieh et al. 2008; 
Jain and Singal 2013; Thankamony et al. 2013). Moreover, a shorter AGD in adult men has 
been related to decreased fertility (Eisenberg et al. 2011), impaired semen quality (Mendiola 
et al. 2011) and decreased serum testosterone levels (Eisenberg et al. 2012). Shortened AGD 
has also been suggested as a biomarker of testicular dysgenesis syndrome (Sharpe 2005).  
28. AGD is included as an endpoint in OECD TG 443 and can therefore be considered 
as an endpoint evaluated to be of human relevance. Moreover ECHA have in a novel 
evaluation stated that: “The findings in AGD, nipple retention and foetal T, suggest an anti-
androgenic mode of action (androgen deficiency) and may be considered as relevant findings 
and predictors of potential adverse effect during human development.” (ECHA 2013). In 
addition, the OECD GD 431 and GD 151 states “A statistically significant change in AGD 
that cannot be explained by the size of the animal indicates effects of the exposure and should 
be considered in setting the NOAEL” (OECD 2008; OECD 2013). As the NOAEL can be 
used as the point of departure for setting safe exposure levels for humans this further supports 
that effects on AGD are of human relevance. Last, but not least the observations of similar 
effects in experimental animals and in humans support that effects on AGD in experimental 
animals are relevant for humans. 
 
                                                     
1 OECD GD 43 (GD on Mammalian Reproductive Toxicity Testing and Assessment; OECD 
2008c) states, “A statistically significant change in AGD that cannot be explained 
by the size of the animal indicates effects of the exposure and should be used for 
setting the NOAEL”. 
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Animal welfare 
29. An important point to remember is that the ability for detection of EDs can for these 
tests (OECD TG 421/422) be enhanced without increasing the number of experimental 
animals used.   
30. Assessment of AGD requires slightly more handling of the new-borns. This 
assessment can be done very gently and is therefore not expected to lead to any animal 
welfare concerns.  
 
Inclusion of AGD in TG 421/422 
31. There are standardized OECD test methods for assessing AGD and the sensitivity 
analysis shows that relevant data can be obtained with the number of litters per group in the 
TGs 421/422. Also, AGD is an endpoint of high human relevance and there are no concerns 
for animal welfare related to the assessment of this endpoint. AGD is normally measured at 
birth (e.g. PD 1-4) and therefore this endpoint can be included in TGs 421/422 without any 
modification of the overall test design.  
32. This all supports that assessment of AGD can be included in TGs 421/422 (OECD 
2015a) (OECD 2015b).  
 
 
Nipple retention 
 
33. Mammary gland development begins similarly in male and female rats; however, the 
further development of the nipple is sexually dimorphic (Kratochwil 1971). Female rats have 
nipples, whereas male rats possess only rudimentary mammary glands but no nipples. This is 
because locally produced dihydrotestosterone (DHT) causes regression or apoptosis of the 
nipple anlagen in male rats (Imperato-McGinley et al. 1985; Imperato-McGinley et al. 1986). 
However, foetal exposure to anti-androgens can block this process, and the male offspring 
displays nipples similarly to their female littermates. Therefore, the retention of nipples in 
male rat pups is an indicator of impaired androgen action during the development. 
34. Assessment of nipple retention (NR) on postnatal day 12 or 13 is included in TG 
443. As TG 421/422 stops on postnatal day 4, we have studied the possibility for assessing 
NR at an earlier time points, e.g. at birth or on postnatal day 4. This does not appear possible 
and thus inclusion of NR in these guidelines would require a 10 days extension of the study 
period, e.g. until postnatal day 13. 
 
Method 
35. Generally, nipples/areolas is defined as a dark focal area (with or without a nipple 
bud) located where nipples are normally present in female offspring (Hass et al. 2007). The 
method for assessing NR is already described in para. 45 in TG 443, i.e.: 
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The presence of nipples/areolae in male pups should be checked on PND 12 or 
13. 
36. Some further guidance is given in GD 151, i.e.: 
Para. 61. Because hair growth makes it difficult, or impossible, to see the 
areolas, it is important to establish the correct time for the assessment. The 
presence of nipples/areolae in male pups should be measured when they are 
obvious (i.e. as they appear in the female litter mates) ideally on PND 12 or 13 
(but this may vary with strain); as far as possible, all pups should be evaluated 
on the same postnatal day as there can be marked differences as maturation 
progresses. Further guidance on assessment of nipple retention is provided in 
GD 43 (OECD 2008, paragraph 91). 
 
Data analysis, sensitivity/power 
37. When examining nipple retention in a study, the nipples could either be recorded as 
a yes/no answer or by counting the number of nipples. Nipple retention is a yes/no endpoint if 
it is expressed as the number of males with or without nipple, but this endpoint can also be 
semi-quantitative, if the number of nipples is recorded (i.e. from 0 to 12). 
38. If only a yes/no answer are used then the power is similar to assessment of 
malformations. Power calculations illustrate that the effect size needed for detection of 
quantal effects has to be 25-37% with 20 litters per group and 50-75% with 8 litters per 
group. This indicates that the sensitivity for detecting effects based on a yes/no answer is 
quite low irrespective of the number of litters included. 
39. This view is also expressed in OECD GD 151 (OECD 2013) where it is stated that: 
A quantitative count in male pups is also recommended as a qualitative assessment only 
(presence/absence) of nipples/areolae may be rather insensitive particularly when control 
incidence is high (for examples, see Gray et al, 2009 and Christiansen et al, 2010). 
40. Power Simulations of nipple retention based on nipple counts have been made and 
are described in appendix 1a. The data are from 20 Copenhagen studies (see para 25). The 
results show that small NR differences can be detected with 8 litters per group if the control 
baseline rate in male rats is close to zero. If the control baseline in male rats is higher (i.e. 2 
nipples) more than 8 litters per group is needed for detection of small NR differences. 
However, the background level of NR is normally very low (close to zero) for the ‘standard’ 
rat strains (e.g. Wistar, Wistar Han, Sprague Dawley). 
 
Human relevance 
41. During the last decade, it has become evident that assessment of both AGD 
(mentioned above) and NR in rodent offspring can be used as markers of impaired androgen 
action within the critical programming windows of sexual differentiation (Welsh et al. 2008, 
Welsh et al. 2010). Both endpoints have been shown to be highly predictive of increased risk 
of adverse reproductive toxicity effects in rats later in life, including increased incidence of 
hypospadias and cryptorchidism, decreased penile length and seminal vesicle weight 
 ENV/JM/MONO(2015)24 
 15 
(Bowman et al. 2003, Christiansen et al. 2008, Welsh et al. 2008), and assessment of both 
AGD and NR has been recognised for regulatory purposes.  
42. Nipple retention or number of nipples are not an observed effect in humans, but the 
relevance of this endpoint is tied to the cause of this effect, which is the ability of chemicals 
to impair androgen action during development.  
 
43. Nipple retention is mandatory in OECD TG 443 (Extended one-generation 
reproductive toxicity study (OECD 2012)) where it is stated: Moreover a statistically 
significant change in nipple retention should be evaluated similarly to an effect in AGD as 
both endpoints indicate an adverse effect of exposure and should be considered in setting a 
NOAEL (ref. GD 151, OECD 2013). As the NOAEL can be used as the point of departure for 
setting safe exposure levels for humans this further supports that effects on NR in 
experimental animals are of human relevance. 
 
Animal welfare 
44. Assessment of NR on PND 12 or 13, if included in the test methods (OECD TG 
421/422), requires handling of the pups on this day. The assessment of each pup can be done 
quickly and gently and is therefore not expected to lead to any animal welfare concerns. 
 
Inclusion of NR in TG 421/422 
45. There are standardized OECD test methods for assessing NR and the sensitivity 
analysis shows that relevant data can be obtained with the number of litters per group in the 
TGs 421/422. Also, NR is an endpoint whose biology and mode of action are relevant to 
humans and there are no concerns for animal welfare related to the assessment of this 
endpoint. This all supports that assessment of NR can be included in TGs 421/422. For the 
OECD TGs 421/422 an extension of the testing period from postnatal day 4 to 12 or 13, i.e. 
9-10 day is necessary as nipple retention has to be assessed on postnatal day 12 or 13. 
46. A quantitative count in male pups is required as a qualitative assessment only 
(presence/absence) of nipples/areolae is regarded as being too insensitive.  
47. However, the presence of nipples/areolae in male pups have to be measured when 
they are obvious (i.e. as they appear in the female litter mates) ideally on PND 12 or 13 (but 
this may vary with strain). Consequently inclusion of this endpoint in OECD TG 421/422 
requires that the observation period is extended from postnatal day 3 to postnatal 12 or 13.  
 
Thyroid hormones 
 
Method  
48. At the time in 2007/2008, when TG 407 was updated, the TG 407 validation data 
was judged insufficient to support inclusion of these particular endpoints as mandatory due to 
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uncertainty about their sensitivity.  Therefore in TG 407 the measurements of thyroid 
hormones (T3,T4 & TSH serum measurements) is optional as it is stated in the beginning of 
para 37 that:  
37. Although in the international evaluation of the endocrine related endpoints 
a clear advantage for the determination of thyroid hormones (T3, T4) and TSH 
could not be demonstrated, it may be helpful to retain plasma or serum 
samples to measure T3, T4 and TSH (optional) if there is an indication for an 
effect on the pituitary-thyroid axis. 
 
49. The situation was different when the new guideline for the extended one-generation 
study was developed in 2010-2011 and assessment of thyroid hormones is included here as 
mandatory. The method is described in paragraph 54 in TG 443, i.e.: 
54. Systemic effects should also be monitored in F1 animals. Fasted blood 
samples from a defined site are taken from ten randomly selected cohort 1A 
males and females per dose group at termination, stored under appropriate 
conditions and subjected to standard clinical biochemistry, including the 
assessment of serum levels for thyroid hormones (T4 and TSH), haematology 
(total and differential leukocyte plus erythrocyte counts) and urinalysis 
assessments. 
 
Data analysis, sensitivity/power 
50. Intensive power simulations similarly as for AGD and NR (appendix 1a) have also 
been performed for TH measurements (Appendix 1b). This analysis was performed 
considering that the blood samples from the sacrificed pups are pooled for males and females 
from the same litter (i.e. one measure per litter), and compared to data sets of gender-specific 
non-pooled measurements. Details about statistical testing and the problematic adjustments to 
p-values for multiplicity, statistical error rates, the power concept and NOAEL determination 
can be found in appendix 1b. It is assumed that all statistical analysis is based on data 
obtained under comparable testing conditions. Data were obtained from US EPA, DTU and 
others (see details in Appendix 1b).  
51. To achieve a better data comparability, all statistical analysis were done on the basis 
of the coefficient of variation (CV), which is defined as the ratio of the standard deviation to 
the mean of the sample. Each individual CV describes the scatter of T4 responses between 
litters from the same control group. The variation of CVs across different studies and for 
different age classes is included in Table 1 in appendix 1b. At PND 3-4 pups, the CVs were 
in the range of 8 up to 77% with median CVs of 8-31% in the data sets. At PND 14-16, the 
CVs were generally lower, i.e. they ranged from 4-33% with median CVs of 6- 13%. The 
revisions in the TGs in relation to assessment of thyroid hormones are based upon the above 
numbers that showed lower CV values in pups at PND 14-16. 
 
52. The statistical analysis showed that detecting a 20% change in a dosed group, 
compared to controls T4 levels is not likely with 10 litters per group, as this requires at least 
17 litters per group. However, there is a high likelihood for detecting a 30% change with 10 
litters per group assuming average data variability (appendix 1b).  
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Human relevance 
53. Thyroid hormones (TH) are needed for proper nerve cell differentiation and 
proliferation, and normal status of these hormones during early development is therefore 
crucial. In humans even moderate and transient reductions in maternal T4 levels during 
pregnancy, may adversely affect the child’s neurological development. The consequences can 
be associated with impaired motor- and neurological function in childhood (Pop et al., 1999; 
Kooistra et al., 2006; Li et al., 2010). Together this indicates that by measuring thyroid 
hormones in TG 421/422 as an indication of thyroid disruption could indeed be relevant for 
human risk assessment. 
54. The rat is by far the most used in vivo model for investigating the toxicity of 
chemicals suspected to disrupt the hypothalamic-pituitary-thyroid axis (HPT axis) (EFSA, 
2011, 2013). However, the relevance of these toxicological rat experiments for humans has 
been a subject for debate for many years (Döhler et al., 1979, Jahnke & Choksi, 2004; 
McClain, 1995). It is well-documented that the general construction of HPT axis is the same 
in rats and humans (Bianco et al., 2002; Zoeller, et al., 2007). However, it is also well-
documented that there are quantitative differences between the HPT axis in the two species. It 
is generally believed that the rat thyroid gland operates at a higher basal activity level than 
humans’. This is mainly based on the more active histological appearance of the thyroid 
follicles in rats compared to primates (McClain, 1995), the lack of a high-affinity transport 
protein (thyroxine-binding globulin) for thyroid hormone in adult rats (Jahnke & Choksi, 
2004) and the lower plasma half-life of the two thyroid hormones (THs) thyroxine (T4) and 
trioidothyronine (T3) in adult rats versus humans (Bianco et al., 2002; Döhler et al., 1979) 
which necessitates a relatively higher production and secretion rate of TH from the thyroid 
follicles in rats to keep circulating TH levels constant. Thyroid disrupting chemicals (TDCs) 
have been shown to decrease circulating levels of THs via various mechanisms and lead to 
adverse health consequences such as thyroid follicular cell tumours and impaired cognition 
and/or motor activity (Miller et al. Zoeller, 2009). It seems widely accepted that the 
formation of thyroid follicular cell tumours in rats due to prolonged elevation of serum 
thyrotropin (TSH) in response to chemical exposure is not relevant to humans (Capen, 1997; 
Dellarco, et al. , 2006; Hurley, et al. , 1998). Developmental neural system impairments 
caused by TDC exposure appear to be independent of TSH and in many instances result from 
transient changes in circulating TH levels (Crofton, 2008). Relevance analysis suggests that 
there is a good degree of interspecies concordance in the mode of actions (MOAs) by which 
these changes in circulating TH occur and the subsequent impairments in the nervous system 
development, at least qualitatively, making rat data on this endpoint relevant for human 
health risk assessment (Crofton & Zoeller, 2005, Lewandowski et al. 2004, Zoeller & Crofton 
2005). 
 
Animal welfare 
ENV/JM/MONO(2015)24 
 18 
55. If blood samples for assessment of thyroid hormones in adults and pups are taken at 
termination of the study (i.e. PND 13-14) this leads to no concern for animal welfare, as trunk 
blood can be collected at the time of sacrifice. In adult animals in TG 407, fasted blood 
samples are to be used and fasting for 20-24 hours in adults only lead to minor concern for 
animal welfare. However, these blood samples are proposed only to be taken in TG 421/422 
if they have not already been taken in a TG 407 study investigating the same compound. The 
TGs 421/422 studies include relatively similar number of adult animals as TG 407 (5-8 per 
dose per sex) and therefore, the overall animal welfare considerations will not increase by 
this assessment and are evaluated as minor. The pups will not be fasted prior to termination 
and blood sampling because fasting of such young pups would lead to major concern for 
animal welfare. 
Inclusion of thyroid hormones in TG 421/422 
56. There are standardized OECD test methods for assessing thyroid hormones. The 
performed power analysis indicated that CVs of about 20 % and sometimes higher, will be 
obtained with the number of litters per group in the TGs 421/422. Lower CVs were seen in 
pups at PND 14-16 compared to PND 3-7. The statistical analysis showed that there is a high 
likelihood for detecting a 30% change in T4 level with 10 litters per group assuming average 
data variability. This may at first glance not seem very sensitive. However due to the 
previously explained species differences in the thyroid hormone system between rats and 
human, exposure to thyroid disrupting compounds may lead to a greater response on hormone 
levels in rats than would be expected in humans, and for example a 30 % change in T4 levels 
is a realistic finding in rats after exposure to a thyroid disrupting chemical. Therefore the 
assessment of TH in the TG421/422 is sufficiently sensitive and can provide relevant data. 
Due to the adverse effects seen in humans after developmental hypothyroidism, this endpoint 
is of high human relevance and there are no concerns for animal welfare related to the 
assessment of this endpoint as long as blood sampling is done in animals that are being 
sacrificed anyway. This all supports that assessment of thyroid hormones can be included in 
TGs 421/422.  
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Abnormalities of external genital organs 
 
Method 
57. In the current TGs 421/422 it is noted that each litter should be examined as soon as 
possible after delivery to establish the number and sex of pups, stillbirths, live births, runts 
(pups that are significantly smaller than corresponding control pups), and the presence of 
gross abnormalities. Thus assessment of abnormalities of genital organs is already to be done. 
However, no details with regard to how to do this are included. 
58. In TG 443 all selected F1 animals are evaluated around sexual maturity and notes 
are taken for any abnormalities of genital organs, such as persistent vaginal thread, 
hypospadias or cleft penis.  
59. We have in a recent project investigated sexual development in male rat offspring 
after in utero exposure to the endocrine disrupting anti-androgen procymidone. The main 
purpose of this study was to investigate whether malformations of the male offspring’s 
genitalia could be scored soon after birth and furthermore to access whether it was possible to 
score the degree of these malformations early after birth. The results (unpublished) presented 
in Appendix 2 shows that malformations of male offspring’s genitalia could be scored early 
after birth (day 0 and day 6). Also, categorisation of the alterations based on the severity of 
the effect was possible. 
 
Data analysis, sensitivity/power,  
60. We have calculated the effect size needed for finding significant effect, i.e. p < 0.05, 
for yes/no endpoints (Table 2). This was done for studies with 8 or 20 litters per group. As 
the evaluation may be done in more than one offspring per litter, the calculations also 
illustrate the effect sizes needed when 2 or 5 offspring per litter is assessed. However, the 
correct effects sizes needed for 2 or 5 animals per litter are likely to be higher than the ones 
shown as our calculation is based on the single pup as the statistical unit. To be correct, the 
calculations should be based on the litter as the statistical unit, i.e. the method should have 
corrected for litter effects. This was unfortunately not possible for us as there are, to our 
knowledge, no available easily used statistical programs for that purpose for quantal data.  
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Table 2. Effect sizes for quantal endpoints needed for p value < 0.05 in one-tailed Fisher 
Exact test* 
Litters per 
group 
Pups per 
litter 
Group No. with 
effect 
No. without 
effect 
Effect size 
      
20 1 Control 0 20 0% 
20 1 Exposed 5 15 25% 
20 2 Control 0 40 0% 
20 2 Exposed 5 35 13% 
20 5 Control 0 100 0% 
20 5 Exposed 5 95 5% 
8 1 Control 0 8 0% 
8 1 Exposed 4 4 50% 
8 2 Control 0 16 0% 
8 2 Exposed 5 11 31% 
8 5 Control 0 40 0% 
8 5 Exposed 5 35 13% 
*The statistics used when more than one male pup per litter is included is based on using the 
pup as the statistical unit. Generally, the litter is considered as the correct statistical unit in 
developmental toxicity studies and using this approach will in most cases lead to even higher 
effect sizes than those shown in the table.  
 
61. The results in table 2 indicate that for achieving a statistically significant effect with 
20 litters per group the frequency of effect in the exposed group has to be 25% with 1 male 
per litter and 5% with 5 males per litter. With 8 litters per group the frequency of effect in the 
exposed group has to be 50% with 1 male per litter and 13% with 5 males per litter. These 
data strongly support that all male pups need to be evaluated, similarly as in OECD TG 414.  
62. This limited sensitivity for detecting significant effects on rare adverse outcomes is 
generally recognized for malformations. Thus, the occurrence of a few similar rare 
malformations such as hypospadias may generally be considered toxicologically relevant 
although the finding is not statistically significant.  
 
Human relevance 
63. In humans recent studies have reported shorter AGD in boys with hypospadias or 
cryptorchidism as compared with boys with normal genitalia (Hsieh et al. 2008). Moreover, it 
is well documented that the incidences of cryptorchidism, hypospadias and testicular cancer 
have increased over the last decades (Giwercman et al. 1993; Skakkebaek et al. 2001; Boisen 
et al. 2005).  
64. Hypospadias in humans is one of the most common urogenital congenital anomalies 
affecting boys (Harris 1990). Prevalence estimates in Europe range from 4 to 24 per 10,000 
births, depending on definition (Dolk et al. 2004) with higher rates of about 5% reported in a 
Danish study (Boisen et al. 2005). Little is known about the aetiology of hypospadias, but a 
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role for EDCs has been proposed, and especially the anti-androgenic EDCs (Baskin et al. 
2001). 
65. Exposure during critical developmental phases such as in utero and in the early 
postnatal period may lead to adverse effects on both reproductive development and 
neurodevelopment. The fact that many of the basic mechanisms underlying this 
developmental process are similar in all mammals indicates that chemicals that have adverse 
effects on reproductive development in rodents should be considered as potential human 
reproductive toxicants as well (Gray 1992). 
 
Animal welfare 
66. Assessment of abnormalities of external genital organs requires slightly more 
handling of the new-borns. This assessment can be done very gently and is therefore not 
expected to lead to any animal welfare concerns. If the assessment is done on PND 12 or 13 
prior to termination of the pups, this can similarly be done very quickly and gently and is 
therefore not expected to lead to any animal welfare concerns. If the assessment of 
abnormalities of external genital organs is done after termination of the pups on PND 12 or 
13, there will obviously be no concern for animal welfare. 
 
Inclusion of abnormalities of external genital organs in TG 421/422 
67. Assessment of abnormalities is already included in TG 421/422. However, no details 
with regard to assessment of abnormalities of external genitals organs are included. The text 
proposed to be added in the revised TG 421 and 422 in relation to abnormalities is modified 
from para 30 in OECD TG 414. 
 
Overall discussion and conclusions 
 
68. The aim of this project was to do a feasibility study for minor enhancements of TG 
421/422 with ED-relevant endpoints. The endpoints considered for inclusion are anogenital 
distance (AGD), nipple retention (NR), thyroid hormones and malformations of external 
reproductive organs in male offspring. 
69. For all endpoints, OECD test methods are available for assessing these.  Power 
analyses have been done showing sufficient sensitivity to get relevant data with the number 
of litters per group in the TGs 421/422. All four endpoints are of relevance for humans as 
described in this review. All four of them are mandatory to assess in some OECD Test 
guidelines used for human risk assessment of chemicals. The overall animal welfare 
considerations will not increase by the assessments of the 4 endpoints. Inclusion of all four 
endpoints in TG 421/422 does not trigger any animal welfare concerns. 
70. In appendix 1a sensitivity of AGD versus Nipple retention is compared in table 4. 
Most often the sensitivity between NR and AGD is equal (13 studies) and only seldom is 
AGD more sensitive than NR (2 studies). However, in almost 30% of the studies (6 out of 21) 
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is nipple retention more sensitive than AGD. Therefore, inclusion of both AGD and nipple 
retention will provide an increased ability for evaluating the potential endocrine disrupting 
activity of a substance compared to having only data for AGD. This is especially relevant in 
cases where equivocal AGD data are found. For the OECD TGs 421/422 an extension of the 
testing period from postnatal day 4 to 12 or 13, i.e. 9-10 day is necessary as nipple retention 
has to be assessed on postnatal day 12 or 13. 
71. The two Test Guidelines have been updated with specific text proposals. Only minor 
changes in study design and only few text changes are necessary to include the assessment of 
anogenital distance (AGD), Nipple Retention (NR), thyroid hormones and malformations of 
external reproductive organs in TG 421/422. 
72. In conclusion, it is feasible to make the proposed minor enhancements of TG 
421/422 with ED-relevant endpoints: anogenital distance (AGD), nipple retention (NR), 
thyroid hormones and malformations of external reproductive organs in male offspring. 
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Appendix 1a. Power Simulations of Nipple Retention and Anogenital Distance of 
Rodents exposed to Endocrine Disrupting Chemicals  
 
 
 
Objective 
 
The objective of this power simulation study was to determine the allocation of animal 
numbers per dose in order to study the effect of certain endocrine disrupting chemicals on 
two endpoints in rodents, nipple retention (NR) and anogenital distance (AGD). The 
conclusions reached are summarized next. Following that is a detailed justification for these 
conclusions, including an introduction of key statistical concepts used in this report, the 
assumptions and constraints on that study, and a description of the data used as basis for the 
simulations. All analysis is based on data obtained under similar testing conditions, as 
outlined in the main report. 
 
Conclusions (always for male pups): 
 
1. Litter variability is an important factor in NR and AGD, and data analysis has to account 
for it. 
2. Body weight of the pup is an important co-factor in analysing AGD differences. Its 
mathematical cubic-root transformation ensures a linear relationship to the measured 
AGD values. 
3. The average AGD size in controls can have an impact on power and the sensitivity of the 
study design. 
4. The sensitivity for detecting AGD differences depends on which minimum AGD 
difference is considered as toxicological significant, and therefore on how AGD values 
are normalized to a relative scale. 
5. Assuming AGD is scaled to the means from both genders, the detection of a 10% 
reduction can be ensured only at high litter numbers. 
6. Intra-litter correlation for NR can be very low, in extreme cases such that litter can be 
ignored in data analysis. 
7. The closer the control baseline rate for NR is to zero, the higher the statistical power is to 
identify very small increases in nipple numbers.  
8. Small NR differences can be detected at low litter sizes and sufficiently low error rates if 
the control baseline rate is close to zero. 
9. Litter is the statistical unit for designing an experimental study, pup is the statistical unit 
for data analysis. This does not mean that litter should be neglected in data analysis, but 
it means that the statistical method should be chosen such that intra-litter variation is 
reflected in the mean effect estimation.  
10. Litter means should not be used in data analysis, but always the pup information.  
11. Reducing the litter size to subsamples can reduce the power dramatically. 
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Description of Data  
 
The majority of data was provided from the same lab (Division of Toxicology and Risk 
Assessment, National Food Institute, Technical University of Denmark) and was produced 
over a period of ten years under various different experimental setups in terms of litter 
numbers, dose numbers, and compounds. Here data were available for both endpoints from 
11 independent studies, and as in some studies more than one compound were tested, 22 data 
sets were considered for data analysis. It should be noted that this comprises not only single 
chemicals, but also well-defined mixtures, as documented in Table 1. The experimental 
design from some studies were optimized for regression modelling and thus contained high 
effect doses which were considered as not relevant for this report and excluded from all data 
analysis (in these studies always more than three treatment doses were used). If not otherwise 
stated, data from a minimum of three treatment doses were available, and for NR only data 
sets were considered if at least one nipple in each treatment group were measured. Due to 
early data availability all power simulations were based on information from this lab only, 
and outcomes were then compared and assessed with data information reported from other 
labs. In total data from 8 other labs were provided, however mainly only for AGD. Here no 
positive results for NR were reported, and therefore considered as not relevant for data 
analysis and informative for power simulations. Often only litter means were reported, with 
no details on how the means were calculated or how many pups were measured, and therefore 
these data sets were not considered for power analysis. The lack of external data for NR must 
therefore be considered as a relevant constrain.  
 
Data analysis and description followed always the same purpose: if possible, establishing a 
NOAEL and LOAEL, and providing information relevant for the simulation studies based on 
the statistical dose-response model and test. The latter involved information about the number 
of litters, the average litter size, model-relevant information such as estimations about the 
within- and between-litter variation, the mean estimates for the NOAEL and LOAEL, and 
post-hoc power analysis. 
 
 
Endpoint Modelling 
 
Common to both endpoints is that pup information from the same litter is likely to be more 
similar than from other litters, which has to be accounted in data analysis. Furthermore, AGD 
is correlated with the body weight of the pup, which also has to be reflected in data analysis. 
Therefore both endpoints are from a statistical point of view more complex than most 
commonly used endpoints in toxicology, and no unique approach exists on how to model and 
analyse them. As consequence not only different methods are available, but the degree of 
model complexity is also subjective. We chose statistical representations which are well-
accepted in the statistical community and most robustness in terms of model assumptions and 
commercial software availability. For the correlated data structure of NR we favoured the 
generalized estimating equation (GEE) model which belongs to the class of marginal models 
(Liang and Zeger, 1986; McCullagh P and Nelder JA, 1989), and for AGD mixed effect 
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models with litter treated as random effects (Littell et al, 2006; Verbeke G and Molenberghs 
G, 2000). For each model a higher model complexity was possible and would have resulted 
occasionally into a better data presentation, however, we consider the data amount available 
in most studies as not sufficient to justify more model parameters, and to our experience its 
impact on the NOAEL determination is minimal.  
 
 
Statistical Testing 
 
In the same way as the statistical modelling of the endpoint can be done in various ways, 
there is no universal or common approach on how to perform the statistical testing for these 
endpoints in order to determine a NOAEL or LOAEL. Crucial is that is depends on the 
endpoint modelling and corresponding model assumptions. The general goal of an 
appropriate test is usually to combine good power behaviour with an easy numerical 
implementation of the test statistics (a problem of particular importance for the 
experimenters) and robustness against specific violations of the test assumptions (e.g., 
normality). Especially in the last decade powerful approaches have been developed, such as 
the so-called Multiple contrast tests (Bretz F and Hothorn LA, 2003). These lead to flexible 
tests that are easy to implement in complex statistical dose-response models and testing 
scenarios, such as AGD and NR (references our papers). Depending on the expected shape of 
the dose-response data, contrast coefficients can be chosen such that they follow certain 
pattern (trend, non-monotony). In this report we used always contrast tests embedded in the 
chosen statistical model, with pairwise single-contrasts in analogy to the Dunnett test. They 
make no assumptions about the shape of the dose-response relationship. For more details see 
Bretz F & Hothorn LA, 2003.  
 
Adjustments to P-values for Multiple Tests 
 
A common problem with comparing more than one treatment group against the same control 
group is that several statistical tests are done and each having the chance of declaring a 
difference between treatment and control to be significant when in fact there is no real 
treatment effect (false positive). Typically, this type of error is set to an acceptance level of 
α=5%, i.e. if the statistical test responds with a p-level below the pre-defined α it is concluded 
that the difference observed between control and treatment means is not due to a chance 
finding. If several tests are done, each with a 5% chance of incorrectly declaring an effect to 
be significant when no true difference exists, then the chance that at least one of these tests 
falsely declaring a significant effect has to be higher than 5%. As a consequence, some 
adjustment is usually made to control the overall chance of at least one of the many tests 
being wrong.  
Some standard statistical tests have built-in adjustments (e.g., Dunnett, Williams and 
Jonckheere test), however, they cannot apply to more complex endpoints such as correlated 
endpoints. The simplest approach to maintain an overall false positive rate is to adjust the p- 
value after the pairwise comparison tests (multiplicity adjustment), and there are several 
adjustment schemes possible (e.g., Bonferroni, Bonferroni-Holm, Hochberg or Sidak). They 
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differ in how well they preserve the overall family-wise error (FWE) rate, and can have a 
huge impact on deciding whether the testing hypothesis of “no treatment” effect can be 
rejected in favour of a likely treatment effect, or not. Moreover, if additional assumptions 
such as monotonicity in the dose-response pattern can be made (“trend”), then even more 
powerful adjustment can be performed (step-down trend procedures). As consequence, the 
chance of overlooking existing treatment effects is increased, and approaches have been 
developed which balances better the false-positive and false-negative rates (so-called false 
discovery rate, FDR).  
The following table provides an example about how adjustment procedures can change raw p 
values: 
 Unadjusted p 
value 
Bonferroni 
adjusted p value 
Hochberg 
adjusted p value 
FDR 
Control - Treatment 1 0.0130 0.0390 0.0390 0.0390 
Control - Treatment 2 0.0325 0.0975 0.0550 0.0488 
Control - Treatment 3 0.0550 0.1650 0.0550 0.0550 
Often the choice of the adjustment is made on practical constraints, such as software 
availability, or the data analyst is not aware about this (even often for statisticians) confusing 
field. As a monotonic trend cannot be guaranteed a priori for the endpoints selected in this 
report, all power analysis was based on unadjusted p values. Depending on how many 
treatment groups are planned for the study, possible p-value adjustments should be taken in 
consideration at the planning stage. 
 
 
Error Rates in Statistical Testing and the Power Concept 
 
Statistical hypothesis tests use data from a sample in order to make inferences about a 
statistical population. Typically for toxicology, we assume as Null hypothesis “no treatment 
effect”, and the aim of the experimental study is to provide sufficient data evidence for 
rejecting the Null hypothesis, and as consequence accepting the alternative hypothesis 
(“treatment effect”). The decision can be done wrongly in two different ways, illustrated in 
the following table: 
 
state of the world
H0 is true
„no effect“
H0 is false
„dose related effect”
results of 
hypothesis 
testing
Accept H0
(no significance)
1-α
(no error)
Type II error β
Reject H0
(significance)
Type I error α 
(significance level)
1-β = power
(no error)
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The probability of rejecting a true null hypothesis (an effect is accepted as significant, while 
in truth no effect exists) is the Type I error, also called the false positive error rate. The 
probability of a Type II error occurring is referred to as the false negative rate (β). Power is 
equal to 1 − β, which is also known as the sensitivity. Most researchers assess the power of 
their statistical tests using 0.80 as default, meaning that the probability for a false negative is 
less than 0.2. This convention implies a four-to-one trade-off between the probability of a 
Type II error and a Type I error, when α=5% is selected as criterion for statistical 
significance. Therefore the power of a statistical test is the probability that the test will reject 
the null hypothesis when the null hypothesis is false (i.e. the probability of not committing a 
Type II error, hence the probability of not making a false negative decision on whether to 
reject a null hypothesis). In other words, power is the probability of finding a difference that 
does exist. 
Power is a function of α, sample size, the effect difference between control and treatment 
mean, and the data variation of the endpoint. It is also conditional of the chosen statistical 
test. Power is strongly influenced by sample size, i.e. if sample sizes are small, the power of 
any test is usually low, and reducing α reduces always the power, i.e. over-controlling type I 
error rates increases the chance of false-negative rates. The greater the data variability, the 
less the statistical power, and the stronger the effect differences of interest, the more likely to 
detect it. Powerful statistical tests can detect small differences, weak tests only large 
differences, and the only way to reduce both error rates at the same time is to increase the 
sample size.  
Power analysis can be used to calculate the minimum sample size required so that one can be 
reasonably likely to detect an effect of a given size. Power analysis can also be used to 
calculate the minimum effect size that is likely to be detected in a study using a given sample 
size. Although these error rates correspond to long-run outcomes, and therefore no guarantee 
is given that the actual study will follow exactly the assumptions made in the power analysis, 
nevertheless one could get a sense of whether the experimental design was a credible one, 
and whether it is likely to minimize the two kinds of errors that are possible in dose-response 
data and, correspondingly, maximize the likelihood of making a correct decision. 
In this report the two error rates were set to α=5% (two-sided) and β=20%, i.e. we assumed a 
power of 80% as minimum.  
 
Simulation studies 
For each endpoint, the power and sample size estimation should be based on the proposed 
dose-response model for the endpoint and data of primary interest. Because of the complex 
statistical nature of both endpoints no exact or approximate mathematical expression exists 
which determines the exact sample size at given power (or vice versa). Therefore it was 
necessarily to perform computer-intensive simulation studies, based on the information 
obtained from all available dose-response data for these endpoints. The power analysis was 
conducted using Monte Carlo simulation, by simulating a complete dose-response data set in 
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which the treatment effect is given, and generating numerous samples that have comparable 
size and variance structure as the actual data. Main assumption for reliable simulation 
outcomes is that the underlying model is a sufficiently accurate representation of the data and 
the study design. The probability of getting a statistically significant result from the model is 
equal to the probability of getting a statistically significant result in the study, that is, the 
statistical power. The probability of a significant result in the model can be calculated by 
repeating the simulation a large number of times and computing the proportion of runs that 
produced significant results. Thus, in order to estimate the statistical power of the test at a 
given effect difference and experimental setup, we repeated the simulation 5000 times at that 
effect size, and recorded the proportion of runs that were statistically significant using the test 
and a significance criterion of α=0.05 (two-sided).  
 
Power simulations can be broken down into three steps: first it requires describing and 
modelling the underlying distribution from which the data are thought to arise. Most often 
this involves making assumptions about the distribution based on empirical results from 
studies that have already been conducted and which share characteristics with the study being 
planned. Using those data it was able to obtain estimates for the nuisance mean model 
parameters, variance-covariance matrix of the random effects, and error variance. As 
variability in the data varies from study to study, we defined an average data scenario 
mirroring average data variability, and a worst-case data scenario assuming an unlikely (but 
not unrealistic) high data variability. The latter allows assessing the impact of high data 
variations on power. The second step is to generate a large number of samples from the 
assumed true noise distribution using various sample sizes that are thought to be adequate to 
achieve the desired power, and the third step is to fit the assumed model to the samples that 
have been generated. For each simulated data set, we perform a hypothesis test and determine 
if sufficient evidence exists to reject the null hypothesis for that sample. Once all sample data 
sets have been processed, we can use the testing results to estimate the power of the test. For 
preliminary simulations where the approximate sample size is not well known, we considered 
a wide range of sample sizes and use smoothing splines to get an approximation of the power 
function. 
 
Anogenital Distance (AGD) 
 
Description of Statistical Model and Estimation Method 
AGD was analysed by mixed effect modelling (LMM), with litter treated as random effects. 
This approach simplifies and unifies many common statistical analyses, including those 
involving repeated measures, random effects, and random coefficients. The basic assumption 
is that the data are linearly related to unobserved multivariate normal random variables. For 
that purpose it was necessary to transform body weight such that it could be used as linear co-
variable. This was realized by the cube root transformation. The cube root is commonly used 
because it is thought that this conversion provides the best comparison between the three-
dimensional end point (weight) and the one-dimensional AGD. No indications were found 
against the normality assumption. In theory, control and treatment groups can have different 
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linear relationship between body weight and their AGD responses. This is certainly justified 
for gender differences (females have a lower AGD to birth weight ratio), and thus likely to be 
the similar case for males at high effect doses. However, for moderate treatment responses we 
found no clear evidence for dose-specific linear relationships between birth weight and AGD, 
and assumed a treatment-independent relationship which was estimated from each data set. 
Figure 1 shows from all male controls their individual birth weights and AGD, together with 
a nonparametric (solid green line) and linear regression fit (solid red line): the agreement 
between both curves indicates that the linearity assumption is justified, and when the linear 
regression is repeated including all control and treatment male pups, the corresponding linear 
regression curve is shifted downwards (dotted red line) without changing significantly its 
steepness (supporting the assumption of a linear relationship independent of the treatment). 
The estimated steepness parameters are reported for all data sets in table 1 (tetBW). 
 
Figure 1: Relationship between birth weight (g) and AGD (units) in male controls 
 
 
Important for performing simulation studies is knowledge about the inter- and intra-litter 
variation. This required a model decision about treatment-specific vs. general estimates for 
these two sources of variation. The first would mean a complex and more accurate modelling 
step, the last would favour a more robust approach. Therefore we estimated for each data set 
both model specifications in order to get an impression about the variation of the treatment-
specific estimations, here the variances. Figure 2 shows for the within-litter variability (A) 
and between-litter variability (B) variance estimates for all data sets, with the treatment-
specific estimates on the x-axis and the overall study estimate on the y- axis. In both cases the 
variation around an overall mean estimate was moderate (horizontal data scatter), justifying 
ENV/JM/MONO(2015)24 
 36 
the assumption of an overall, treatment-independent estimate for the within-litter and 
between-litter AGD variability. 
 
Figure 2: AGD in male pups – treatment-independent study variability vs. treatment 
variability, shown for within-litter variability (A) and between-litter variability (B). 
 
 
 
 
To define an average and worst-case scenario for the power simulations, all estimates for 
within-litter and between-litter variances are plotted in Figure 3. The sum of both estimates 
defines the total variance of the mean AGD estimates. Typically, most dots are below the 
trend line, suggesting that the main variation of AGD measurements arises from the litter, and 
not from between litters. For the power simulation studies we set Variancebetween litter=0.87 and 
Variancewithin litter =1.64 for an average data variability scenario, and Variancebetween litter=2.3 
and Variancewithin litter =2.3 defining a worst-case data variability scenario. 
 
All data analyses were performed by using the MIXED procedure in the statistical software 
SAS.  
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Figure 3: Anogenital distance in male pups – within-litter vs. between-litter variability, 
with circles defining the typical and worst-cast variability settings used for power 
simulation. 
 
 
 
Description of Simulations 
 
Using the model described above, we simulated data for litter sizes from 5 to 20. For each 
sample size, 5000 samples were generated and analysed using different mean AGD responses 
for the controls. As effect differences of interest 10% and 20% reduction on the relative AGD 
scale normalized to both gender controls were selected. The underlying concept behind the 
simulations is described in detail by Stroup (1999) which uses the Non-Central parameter of a 
Non-Central F-Distribution to generate correlated random samples according to the pre-
defined between-litter and within-litter variances. This reduces significantly the time needed 
for a single simulation step, and allows the analyses of various experimental setups in a 
relatively short time.  
 
We used three different scenarios for the litter sizes: either they were hold fixed at 2 and 8, 
respectively, simulating extreme litter sizes, or in a third scenario they were resampled by 
random out of a pool from all observed control litter sizes. The resulting variation of this 
variable litter size setting is summarized by box whisker plots, with boxes representing the 
quartiles of the simulation outcomes and the whiskers the 5th percentile and the 95th 
percentiles. Birth weights were resampled with replacement out of a pool of all measured 
male control pups. Their linear relationships to AGD were defined by setting the 
corresponding model parameter tetBW to 9.57. 
 
All data analyses were performed by using the IML procedure in the statistical software SAS.  
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Table 1: AGD – Dose-Response summary (Copenhagen studies) 
                  
   litter birth weight Model information (LMM) AGD (units) Control difference   
Study type of treatment dose 
# av. 
size 
 
mean 
90% 
percentile 
between-
litter 
variance 
within-
litter 
variance 
ILC tetBW mean 
 
SEM abs ratio norm post-hoc 
power 
 
                 
A male control  7 5.4 6.36 [5.80-6.80]     21.33 0.698 0 1 1 -  
 compound A NOAEL1) 10 4.1 5.98 [5.20-6.60] 1.98 2.50 0.44 9.01** 19.67 0.441 -1.66 0.92 0.84 31.9%  
 female control  8 5.2 5.93 [5.40-6.30]     11.08 0.333 -10.25 0.52 0 -  
B male control  13 4.8 6.32 [5.80-7.00]     21.40 0.142 0 1 1 -  
 compound B NOAEL 6 5.8 6.27 [5.80-6.70] 0.63 0.81 0.44 8.91** 21.03 0.389 -0.37 0.98 0.96 12.6%  
  LOAEL 6 4.2 6.40 [5.70-6.90]     19.53** 0.371 -1.87 0.91 0.82 98.9%  
 compound C LOAEL2) 7 4.0 6.24 [5.70-6.90] 0.88 1.01 0.46 6.24** 19.38** 0.422 -2.02 0.91 0.80 97.9%  
 female control  13 5.8 6.01 [5.40-6.60]     11.09 0.112 -10.31 0.52 0 -  
C male control  15 4.7 6.42 [5.35-7.00]     22.48 0.409 0 1 1 -  
 compound D NOAEL 8 4.4 6.41 [5.70-7.00] 2.43 2.12 0.53 14.93** 20.56 0.583 -1.93 0.91 0.82 59.7%  
  LOAEL 8 4.9 6.21 [5.80-6.60]     19.17** 0.583 -3.32 0.85 0.68 94.2%  
 compound E LOAEL2) 8 4.1 6.55 [6.00-7.10] 2.17 2.20 0.50 12.92** 20.75* 0.537 -1.73 0.92 0.84 72.2%  
 female control  13 5.7 6.10 [5.60-6.50]     11.98 0.397 -10.51 0.53 0 -  
D male control  15 4.3 6.23 [5.50-6.90]     20.68 0.325 0 1 1 -  
 compound F NOAEL1) 7 4.7 6.20 [5.40-6.70] 1.24 1.56 0.44 9.40** 20.69 0.636 0.01 1 1 31.7%  
 compound G NOAEL1) 8 4.8 5.84 [4.80-6.70] 1.00 1.59 0.39 5.32** 19.70 0.408 -0.98 0.95 0.91 24.7%  
 compound H NOAEL 8 6.4 6.23 [5.70-6.90] 0.87 1.65 0.35 7.52** 19.78 0.364 -0.90 0.96 0.91 36.5%  
  LOAEL 5 5.2 6.18 [5.50-6.60]     17.96** 0.410 -2.72 0.87 0.74 97.9%  
 female control  15 5.1 5.95 [5.30-6.60]     10.32 0.262 -10.36 0.50 0 -  
E male control  13 4.8 6.19 [5.70-6.80]     19.97 0.440 0 1 1 -  
 Mixture A NOAEL 14 5.3 5.85 [5.40-6.40] 1.50 1.65 0.48 5.60** 19.08 0.400 -0.89 0.96 0.90 29.4%  
  LOAEL 15 4.7 6.20 [5.40-6.90]     18.23** 0.357 -1.75 0.91 0.81 82.8%  
 female control  14 5.5 5.97 [5.50-6.70]     10.68 0.264   0 -  
F male control  13 4.5 6.07 [5.40-6.60]     20.67 0.270 0 1 1 -  
 compound I NOAEL1) 7 3.9 6.28 [5.60-6.90] 1.07 1.91 0.36 14.95** 21.25 0.805 0.59 1.03 1.06 12.6%  
 compound J NOAEL1) 7 5.0 5.84 [5.30-6.40] 1.16 1.63 0.42 9.06** 20.63 0.445 -0.04 1.00 1.00 20.6%  
 Mixture B LOAEL2) 16 5.6 6.19 [5.40-6.80] 0.88 1.56 0.36 4.79* 19.22** 0.192 -1.45 0.93 0.85 95.5%  
 female control  13 5.2 5.71 [5.00-6.40]     10.80 0.193   0 -  
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   litter birth weight Model information (LMM) AGD (units) Control difference   
Study type of treatment dose # 
av. 
size mean 
90% 
percentile 
between-
litter 
variance 
within-
litter 
variance 
ILC tetBW mean SEM abs ratio norm 
post-hoc 
power 
 
                  
G male control  13 5.2 6.25 [5.40-7.00]     20.61 0.139 0 1 1 -  
 Mixture C 3) NOAEL1) 14 5.9 6.38 [5.80-6.90] 0.17 1.67 0.09 7.57** 20.48 0.245 -0.13 0.99 0.99 16.7%  
 female 
control 
 14 6.1 6.00 [5.30-6.50]     10.31 0.089   0 -  
H male control  19 5.5 6.29 [5.60-6.90]     21.57 0.215 0 1 1 -  
 Mixture D NOAEL 19 5.2 6.25 [5.70-6.80] 0.79 1.61 0.33 7.71** 21.24 0.253 -0.33 0.98 0.97 12.5%  
  LOAEL 14 6.0 6.53 [6.00-7.20]     20.83* 0.242 -0.74 0.97 0.93 59.5%  
 Mixture E 3) LOAEL2) 15 4.9 6.44 [5.80-7.00] 0.37 1.71 0.18 8.74** 21.06* 0.229 -0.51 0.98 0.95 52.7%  
 Mixture F 3) NOAEL1) 17 5.2 6.24 [5.60-6.80] 0.81 1.64 0.33 8.46** 21.92 0.321 0.35 1.02 1.03 24.9%  
 female 
control 
 20 5.9 5.96 [5.10-6.50]     10.87 0.129   0 -  
I male control  18 6.4 6.22 [5.60-7.10]     24.61 0.088 0 1 1 -  
 compound K LOAEL2) 21 5.7 6.28 [5.50-6.80] 0.37 0.46 0.44 3.64** 24.17* 0.121 -0.44 0.98 0.96 59.4%  
 female 
control 
 19 5.6 5.85 [5.20-6.50]     13.57 0.110   0 -  
J male control  15 4.9 6.37 [5.70-6.90]     24.00 0.172 0 1 1 -  
 compound L NOAEL 13 6.1 6.43 [5.70-7.00] 0.97 0.44 0.69 8.99** 24.12 0.161 0.13 1.01 1.01 0.8%  
  LOAEL 15 6.0 6.59 [6.00-7.10]     22.85** 0.300 -1.14 0.95 0.89 92.8%  
 female 
control 
 15 5.7 6.11 [5.60-6.60]     13.42 0.116   0 -  
K male control  15 5.0 6.47 [5.70-6.90]     21.98 0.239 0 1 1 -  
 Mixture G 3) LOAEL2) 16 5.6 6.49 [5.35-7.20] 0.39 1.77 0.18 9.35** 20.50** 0.187 -1.48 0.93 0.86 99.5%  
 Mixture H 3) NOAEL1) 16 5.0 6.51 [5.60-7.15] 0.70 1.76 0.28 9.66** 21.50 0.282 -0.48 0.98 0.95 19.6%  
 Mixture I 3) LOAEL2) 17 5.9 6.17 [5.50-6.90] 0.40 1.91 0.17 6.34** 20.73** 0.190 -1.25 0.94 0.88 89.7%  
 female 
control 
 14 5.4 6.16 [5.50-6.80]     11.37 0.124   0 -  
                  
ILC=inter-litter correlation; * stat. significant at α=5%; ** stat. significant at α=1%; 
1) all doses produced significant responses, values for the lowest dose are shown;  2) all doses produced non-significant responses, values for the highest dose 
are shown;  3) only two treatment doses were tested; tetBW model parameter estimated for cubic root-transformed body weight; 
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Outcomes of the power simulations 
The outcomes of the power simulations are summarized for control pups with high AGD 
estimates in Figure 4 (males: 24.61 units, females: 13.57 units), and for control pups with a 
low AGD baseline in Figure 5 (males: 20.00 units, females: 10.70 units). For these two 
scenarios two treatment-related relative reductions to the male controls were investigated, 
10% (A) and 20% reduction (B), with both reductions related to the difference between male 
and female controls. In Figure 4A the 10% reduction corresponds to a 4.5% reduction in 
relation to the control male AGD (i.e. ratio between 1.104 and 24.61), while the 10% 
reduction in Figure 5B corresponds to a 4.65 % reduction in relation to the control male 
AGD. Similarly for the 20% reductions, they correspond to a 9% reduction (Figure 4B) and 
9.3% reduction (Figure 5B), respectively.  
If the detection of a 20% reduction at high likelihood is of interest (power > 80%), only small 
sample sizes up to 9 litters are required, without increasing the false-positive error rate. This 
assumes that all pup information is used for data analysis. However, smaller effect sizes are 
likely to be harder to detect, the power analysis suggests that a 10% reduction will only be 
detected with a sufficient certainty if the AGD information from at least 16 litters is available 
and the individual variation follows the average pattern. Ideally the control AGD should then 
be also not too low.  
Whereat in the previous figures the effect size of interest was given (10 and 20% reduction, 
respectively) and the power was estimated in dependence of the sample size (litter numbers), 
we also analysed the reverse situation by fixing the power and estimating the effect size in 
dependence of the sample size (litter numbers), i.e. the sensitivity. The results are shown in 
Figure 6, again for relatively large AGD units in the controls (top figure) and small ones 
(bottom). Here we focused only on average litter sizes, resampled from all available data sets, 
but again for a typical data variability scenario (green curve) and a worst-case (red curve). 
The horizontal lines correspond to the control AGD means. Any effect difference between the 
male control line and the curves is unlikely to be detected as statistically significant, at least 
at given 80% power.  
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Figure 4: Power simulation for male pups with high AGD control estimates. 10% reduction 
corresponds to a 4.5% reduction in relation to the control male AGD, while the 20% reduction 
correspond to a 9% reduction in relation to the control male AGD. 
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Figure 5: Power simulation for male pups with low AGD control estimates. 10% reduction 
corresponds to a 4.65% reduction in relation to the control male AGD. 20% reduction 
corresponds to a 9.3% reduction.
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Figure 6: Statistical detection limit (sensitivity) at given power (80%) and false-positive 
error rate α=5%. Large and small pups refer to the average AGD sizes from the male 
controls as mentioned in the previous figures. 
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AGD Data from other labs 
Data sets from 7 studies were analysed and outcomes were compared with that from the 
Copenhagen studies. Only in two studies significant treatment effects were detected, with 
different directions compared to their controls: study C revealed an increase in AGD, study D 
a reduction in AGD (Table 2). Most studies were performed with huge numbers of damns, 
litter numbers ranged from 24 up to 30. The litter sizes and birth weights were comparable to 
the previous results (exception: study F), however, significant differences were between the 
mean AGD estimates and their variance components: the between-litter as well as within-
litter variances were smaller by a factor of 10-100. The reasons for these gross differences are 
unknown, but probably indicate that AGD values were reported in a different unit. It should 
be also noted that AGD values were often reported as rounded values. Based on these values 
the power simulation studies were repeated, with setting Variancebetween litter=0.04 and 
Variancewithin litter =0.06 for an average data variability scenario, and Variancebetween litter=1.5 
and Variancewithin litter =1.5 for a worst-case data variability scenario, results are shown in 
Figure 7. Here a 10% reduction corresponds to a 5% reduction in relation to the control male 
AGD, while the 20% reduction corresponds to a 10% reduction in relation to the control male 
AGD. 
All simulations on the basis of these data sets indicate that the detection of effect sizes at 
same error rates as in the previous simulations requires much higher sample sizes, and a 10% 
reduction is likely to be overlooked by litter sizes below 20.  
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Table 2: AGD – Dose-Response summary (Non-Copenhagen studies) 
                  
   litter birth weight Model information (LMM) AGD (mm) Control difference   
Study type of treatment dose 
# av. 
size 
 
mean 
90% 
percentile 
between-
litter 
variance 
within-
litter 
variance 
ILC tetBW mean SEM abs ratio norm post-hoc 
power 
 
                 
A male control  27 7.1 7.30 [6.60-8.20]     3.91 0.052 0 1 1 -  
 Compound NOAEL1) 24 7.8 7.05 [6.10-8.10] 0.051 0.101 0.34 1.89** 3.74 0.052 -0.17 0.96 0.91 32.4%  
 female control  27 6.1 6.96 [6.00-7.80]     2.08 0.049 -1.83 0.53 0 -  
B male control  26 6.5 7.31 [6.30-8.30]     3.88 0.078 0 1 1 -  
 Compound NOAEL1) 26 6.3 7.20 [6.20-8.00] 0.155 0.142 0.52 1.76** 3.87 0.083 -0.01 1.00 0.99 17.5%  
 female control  26 6.4 6.86 [5.90-7.80]     2.08 0.053 -1.80 0.54 0 -  
C male control  26 5.4 6.11 [5.50-6.85]     3.48 0.056 0 1 1 -  
 Compound NOAEL 30 5.3 6.27 [5.80-6.80] 0.076 0.059 0.56 1.37** 3.55 0.056 0.07 1.02 1.05 9.8%  
  LOAEL 28 5.3 6.01 [5.20-6.70]     3.68 0.055 0.20 1.06 1.14 74.7%  
 female control  26 5.5 5.76 [5.10-6.60]     2.03 0.016 -1.44 0.58 0 -  
D male control  28 5.5 6.25 [5.60-7.00]     3.80 0.027 0 1 1 -  
 compound NOAEL 27 5.9 6.15 [5.40-7.00] 0.030 0.066 0.31 1.05** 3.78 0.029 -0.02 1.00 0.99 40.4%  
  LOAEL 29 5.6 5.94 [5.40-6.70]     3.64 0.052 -0.16 0.96 0.91 66.7%  
 female control  28 4.9 5.98 [5.30-6.70]     2.06 0.025 -1.74 0.54 0 -  
E male control  27 5.0 6.12 [5.30-6.90]     3.43 0.041 0 1 1 -  
 compound NOAEL1) 28 4.8 5.88 [5.20-6.50] 0.038 0.058 0.39 1.57** 3.47 0.044 0.04 1.01 1.03 51.4%  
 female control  27 5.6 5.79 [5.20-6.40]     1.68 0.033 -1.75 0.49 0 -  
F male control  27 4.9 6.21 [5.60-6.90]     4.13 0.051 0 1 1 -  
 Compound NOAEL1) 30 4.2 6.22 [5.50-6.90] 0.041 0.060 0.40 1.32** 4.21 0.041 0.09 1.02 1.04 24.5%  
 female control  27 5.4 5.85 [5.20-6.30]     2.11 0.037 -2.01 0.51 0 -  
G male control  10 6.8 10.39 [8.90-11.90]     4.62 0.103 0 1 1 -  
 female control  10 5.9 9.60 [8.60-10.90]     2.28 0.049 -2.33 0.49 0 -  
                  
ILC=inter-litter correlation; * stat. significant at α=5%; ** stat. significant at α=1%; 
1) all doses produced significant responses, values for the lowest dose are shown;  2) all doses produced non-significant responses, values for the highest dose 
are shown; 
3) only two treatment doses were tested; tetBW model parameter estimated for cubic root-transformed body weight; 
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Figure 7: Power simulation for AGD in male pups. 10% reduction corresponds to a 5% 
reduction in relation to the control male AGD. 20% reduction corresponds to a 10% reduction
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Nipple Retention 
 
Description of Data 
 
Data sets from 20 studies were analysed, the summarizing information is shown in Table 3. 
The number of litters and average litter sizes were nearly identical to that reported in Table 1 
for AGD. If data variability was small, average nipple numbers of below 1 could be detected 
as statistically significantly different from the controls. Litter correlations ranged from 0 to 
0.5, indicating a weak to moderate intra-litter variation. 
 
 
Description of Statistical Model and Estimation Method 
 
The analysis of correlated data when the measurements are assumes to be multivariate normal 
has been studied extensively. However, when the responses are discrete and correlated, as 
this is the case for the number of nipples, different methodologies must be used in the 
analysis of data. As a general and flexible method for correlated discrete data, the generalized 
estimating equations (GEE) approach has become increasingly important and widely used in 
analysing such data (Liang & Zeger, 1986). In addition to those with the GEE approach there 
are other estimation approaches (e.g., weighted least squares), but here we only consider the 
GEE approach due to its increasing use in the field. The number of nipples/areolas was 
assumed to follow a binomial distribution with a response range between 0 and 12, with the 
latter being equal to the biologically possible maximal number of nipples in rats.  
 
An attractive property of GEE is that working correlation matrix can be miss-specified and 
yet the regression coefficient estimator is still consistent and asymptotically normal. The 
covariance matrix of the estimated regression coefficients was estimated using the so called 
robust or sandwich estimator, the working correlation structure was chosen according to the 
working independence model. The correlated data can then be treated as though they were 
independent and the resulting regression parameter estimates along with the robust 
covariance estimator can be used to draw proper statistical conclusions. In general there is no 
closed form available which would allow sample size and power calculation in GEE (except 
for some special cases, but not relevant here). Note that one needs to specify the underlying 
correlation structure in sample size and power calculations and thus can use it as the working 
correlation structure.  
 
Main assumption is that the pups from the same litter are correlated while litters are 
independent, i.e. within-litter correlation is present, but observations from different litters are 
independent. The number of nipples per pup was modelled by the marginal logistic regression 
model, where the unknown regression coefficients corresponded to the control and treatment 
mean estimates. We assumed that the correlation structure does not change across the litters, 
i.e. all pups had the same treatment-independent correlation (exchangeable compound 
symmetry matrix). The correlation parameter is defined between -1 and 1, with 1 assuming 
full correlation (all pups from the same litter responded in the same way), 0 no correlation at 
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all, and negative values indicate negative relationships. The latter was ruled out from a 
biological point of view, and consequently the correlation parameter was assumed to be 
positive, i.e. pups from the same litter are likely to respond more similar. This property can 
be translated as justification of using the litter mean in statistical analysis when the 
correlation parameter is close to 1, and using the pup response as statistical unit when the 
parameter is close to 0. Values between these two extremes therefore provide an estimate 
about the importance of the factor litter in data analysis, and its setting is crucial for sample 
size and power calculation. The between-litter variability (“variance estimate”) was derived 
from the inference of the mean estimates, and used to define the variability scenarios for the 
power simulation studies. 
 
Non-variation in the controls is problematic for statistics, i.e. if for none of the pups a nipple 
was measured. In a strict sense no data analysis can be done then. To overcome this 
limitation, a pragmatic solution might be setting a positive nipple for at least one pup per 
treatment group. However, for none of the selected data sets this was required. 
 
All data analyses were performed by using the GENMOD procedure in the statistical 
software SAS.  
 
 
Description of Simulations 
 
For the Monte Carlo approach it was necessary to develop a method to simulate high-
dimensional correlated data, in our case a high-dimensional multivariate binary distribution 
that describes the whole litter. This was achieved by using the copula techniques which 
combines marginal distributions with a given correlation structure (for more details see R. 
Wicklin, 2013). In contrast to the power simulation studies for AGD no approximate test 
statistics were available that could have simplified the simulation studies, and consequently 
the computer time required for the simulation studies was immense. This meant that it was 
not possible to estimate the detection limit at given error rates, only figures showing the 
power for specific experimental setups and data variability assumptions were produced. In 
each simulation step litter size was resampled by random out of a pool of all observed litter 
control sizes. All data analyses were performed by using the IML procedure in the statistical 
software SAS.  
 
 
Results 
 
The outcomes of the power simulations are shown for male controls with a small nipple 
baseline (0.1 nipples per pup) for two different variability scenarios in Figure 8, assuming the 
detection of 1 nipple per pup as effect size of interest. Here 10 litters per dose should be 
sufficient to ensure the statistical detection of this effect size. For the higher base line of 2 
litters per control pup the detection of effect differences becomes much more difficult, and an 
increased nipple variability allows is likely to detect only large effect differences (Figure 9): 
 ENV/JM/MONO(2015)24 
 53 
the detection of 4 nipples per pup at high data variability is unlikely to be achieved with litter 
numbers below 20. The negative impact of increased control baseline rates on statistical 
power is well-known from cancer studies with dichotomous tumour endpoints. 
 
Table 3: Nipple Retention Summary for all Copenhagen studies 
   litter  model information   
Study type of treatment dose 
# average 
size 
mean 
nipple 
 logit link Variance 
estimate 
Litter 
correlatio
n 
Control 
difference 
post-
hoc 
power 
            
A male control  7 5.4 2.31  -1.533 0.0150    
 compound A NOAEL 8 4.4 1.95  -1.736 0.0161 0.056 -0.36 22.3% 
  LOAEL 10 5.1 2.85*  -1.268 0.0097 0.056 0.54 53.0% 
B male control  13 3.8 0.02  -6.484 0.9219    
 compound B LOAEL2) 5 5.8 0.89*  -2.611 0.1408 0.331 0.87 57.4% 
 compound C LOAEL2) 7 3.4 1.28*  -2.215 0.1232 0.367 1.26 60.9% 
C male control  15 4.1 0.23  -4.030 0.1334    
 compound D NOAEL 8 4.0 0.89  -2.615 0.3885 0.350 0.66 13.8% 
  LOAEL 8 3.8 3.95**  -0.829 0.1047 0.350 3.72 96.7% 
 compound E LOAEL2) 8 3.6 3.78**  -0.890 0.1052 0.332 3.55 98.0% 
D male control  15 4.3 0.40  -3.461 0.4052    
 compound F NOAEL1
) 
6 5.2 2.66  -1.356 0.0826 0.506 2.26 15.3% 
 compound G NOAEL1
) 
8 4.0 0.89  -2.608 0.2413 0.409 0.49 5.1% 
 compound H NOAEL 8 5.3 1.38  -2.127 0.0532 0.248 0.98 9.5% 
  LOAEL 5 4.6 3.72*  -0.913 0.1291 0.248 3.32 50.7% 
E male control  13 4.8 0.02  -6.612 0.9072    
 Mixture A LOAEL2) 14 4.4 1.01**  -2.478 0.0623 0.140 0.99 99.9% 
F male control  13 3.8 1.60  -1.965 0.0847    
 compound I NOAEL1
) 
7 3.0 3.61  -0.942 0.0915 0.212 2.01 29.3% 
 compound J NOAEL1
) 
7 4.3 3.08  -1.168 0.0869 0.462 1.48 1.5% 
 Mixture B LOAEL2) 16 4.8 3.65*  -0.950 0.0554 0.385 2.05 95.2% 
G male control  13 4.3 0.06  -5.333 0.1341    
 Mixture C 3) NOAEL1
) 
14 5.9 0.53**  
-3.151 0.0710 
0.128 0.47 93.1% 
H male control  19 4.4 0.01  -6.997 0.9399    
 Mixture D NOAEL1
) 
19 4.6 0.69  -2.877 0.1187 0.104 0.68 44.3% 
 Mixture E 3) LOAEL2) 15 4.6 1.13*  -2.352 0.0447 0.048 1.12 71.4% 
 Mixture F 3) NOAEL1
) 
17 5.2 0.04  -5.667 0.2497 <0.01 0.03 2.3% 
I male control  18 6.3 0.09  -5.011 0.1682    
 compound K NOAEL2
) 
17 6.3 0.43  -3.371 0.1226 0.121 0.34  
K male control  15 5.1 0.14  -4.553 0.1798    
 Mixture G 3) LOAEL2) 16 5.6 0.66**  -2.926 0.0711 0.173 0.52 94.9% 
 Mixture H 3) NOAEL1
) 
16 4.9 0.14  -4.492 0.1312 0.034 0.00 0.5% 
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 Mixture I 3) LOAEL2) 17 5.8 1.55**  -1.997 0.0268 0.139 1.41 99.9%. 
            
* stat. significant at α=5%; ** stat. significant at α=1%; logit link = mean model estimate after logit 
transformation; 1) all doses produced significant responses, values for the lowest dose are shown;  2) all 
doses produced non-significant responses, values for the highest dose are shown;  3) only two 
treatment doses were tested; 
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Figure 8: Power simulation for nipple retention in male pups with low control baseline. 
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Figure 9: Power simulation for nipple retention in male pups with high control baseline. 
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Comparison AGD vs. NR 
The successful NOAEL and LOAEL determinations for all studies are shown in Table 4. If 
only a NOAEL was derived, then none of the tested doses produced responses significantly 
different from the controls, and if only a LOAEL was determined, then all of the tested doses 
produced statistically significant responses. Also included is whether the NOAELs agreed for 
both endpoints, or whether different conclusions were drawn.      
 
Table 4: NOAELs & LOAELS for AGD and NR and their comparative assessment 
  AGD NR  comparative assessment (“sensitivity”) 
Study type of treatment NOAEL LOAEL NOAEL LOAEL  NR < AGD NR = AGD AGD < NR 
          
Copenhagen studies 
A compound A X - X X  X   
B compound B X X - X  X   
 compound C - X - X   X  
C compound D X X X X  X   
 compound E - X - X   X  
D compound F X - X -   X  
 compound G X - X -   X  
 compound H X X X X   X  
E Mixture A X X - X  X   
F compound I X - X -   X  
 compound J X - X -   X  
 Mixture B - X - X   X  
G Mixture C X - - X  X   
H Mixture D X X X -    X 
 Mixture E - X - X   X  
 Mixture F X - X -   X  
I compound K - X X -    X 
J compound L X X X -  X   
K Mixture G - X - X   X  
 Mixture H X - X -   X  
 Mixture I - X - X   X  
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APPENDIX 1 
POWER SIMULATIONS OF T4 HORMONE LEVELS OF RODENTS EXPOSED TO 
ENDOCRINE DISRUPTING CHEMICALS 
 
 
 
Objective 
This power study is an extension to the report Power Simulations of Nipple Retention and 
Anogenital Distance of Rodents exposed to Endocrine Disrupting Chemicals (Annex 1a), with 
the objective to determine the optimal allocation of litter numbers per dose in order to study 
the effect of certain endocrine disrupting chemicals on Thyroid hormone blood levels (T4) 
measured in pups and dams. This analysis was performed considering that the blood samples 
from the pups killed are pooled for males and females from the same litter (i.e. one measure 
per litter), and compared to data sets of gender-specific non-pooled measurements. The 
conclusions reached are summarized next, followed by a detailed justification for these 
conclusions. Details about statistical testing and the problematic adjustments to p-values for 
multiplicity, statistical error rates, the power concept and NOAEL determination can be 
found in the first report and are here not described. It is assumed that all statistical analysis is 
based on data obtained under comparable testing conditions, as outlined in the main report.  
 
Conclusions: 
1. Conclusions about intra-litter variability could not be drawn, and thus no statement about 
the statistical uncertainty of a litter mean. As consequence it is unclear what the optimal 
allocation of pups for the estimation of a litter mean is. The litter mean is considered as 
an independent non-random variable in data analysis.  
2. Data from DTU revealed in average the smallest variability between T4 litter means. The 
reasons for the differences in litter mean variations between DTU and the other labs are 
unknown. 
3. Variability between litter means can be huge (CV>60%), and it is unclear whether this is 
caused by biological or technical factors.  
4. T4 litter responses are more homogenous from controls and older pups. 
5. Variability is likely to be higher at high effect doses. 
6. Pooling T4 levels from pups from the same litter provided no sound indications for a 
more robust litter mean estimation if compared to using only one pup per litter. 
7. In none of the studies gender-specific differences in the T4 levels were detected in the 
control animals, but two studies revealed under dosing statistically significant different 
T4 responses between the sexes.  
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8. The detection of T4 changes by 20% might be too optimistic, as it assumes a rather low 
to moderate data variability for this endpoint (CV <= 20%). In worst case (CV=60%), 
even with high litter numbers (N<30) a 50% T4 change might be undetected.  
Hint: All statistical analyses were done on the basis of the coefficient of variation (CV). 
 
Data availability 
 
The majority of data were provided from DTU (Division of Toxicology and Risk 
Assessment, National Food Institute, Technical University of Denmark) and US EPA, 
remaining data sets were made available from two member of the OECD expert group.  
Data from the US EPA was based on T4 levels derived from pooled tissue samples from an 
equal number of male and female pups from the same litter, and measured at different 
developmental stages of the pups. In addition T4 levels were measured in dams (at birth and 
PND21). Litter mean was considered always as the statistical unit, and data summaries were 
provided for each control or treatment groups, expressed as litter means plus standard 
deviation (or standard error of the mean) and corresponding litter number. This suggests that 
data have been tested for normality. Litter number per control or dose group varied between 5 
and 26. All data have been published. 
Data provided from DTU were from three different studies (Wistar rat), where in two studies 
T4 levels were measured from one pup per litter and for both sexes, at different pup ages, and 
from the dams, otherwise T4 levels were pooled from male and female pups from the same 
litter. The number of litters in the investigated dose groups varied between 5 and 20. A 
different method for measurement of T4 levels was used in the first DTU study, compared to 
the last two. None of these data have been published. 
Remaining data sets were from three studies, with measurements from the pups at PND4 (test 
species not reported), and litter means determined on the basis of pooling or individuals. Both 
studies included 4 treatment doses, with data available from 8-20 litter per group.   
Data means with reported zero standard deviation or CVs above 100% were excluded from 
all data analysis. The latter might indicate the overlooked presence of an outlier in the rough 
data. Samples with less than 5 litters were also excluded from data analysis. It should be 
noted that at high effect doses occasionally levels below the limitation of quantification 
(LOQ) were measured, which might have violated the ANOVA assumptions and thus 
resulted into unreliable CV estimations. Furthermore, control levels in pups from GD0-GD4 
are generally lower than from later stages, and therefore reducing the range of possible T4 
reductions.  
Data treatment 
T4 levels were measured at different developmental stages in pups and dams and from 
different rodent species, and data were provided in different units (ng/ml, nM). To achieve a 
better data comparability, all statistical analysis were done on the basis of the coefficient of 
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variation (CV), which is defined as the ratio of the standard deviation to the mean of the 
sample. However, as most sample sizes can be considered from a statistical point of view as 
rather small, this calculation leads to biased estimator. Therefore the CV calculation was 
corrected as   
corrected
1CV 1 *CV
4* N
 = + 
 
, 
with N sample size (Sokal RR & Rohlf FJ, 1995). As consequence, the lower the sample size, 
the larger the correction, e.g. at N=10 the CV is increased by a factor of 2.5%. In the 
following CV refers always to this equation. T4 measurements were always normalized to the 
control mean, and only these values were used in power analysis, i.e. responses are expressed 
as relative to the control mean.  
Data description and analysis followed always the same purpose: identifying a reference 
measure of data variability for the power and sample size analysis. As no intra-litter 
information was available (i.e. more than one T4 measurement per litter), the CV always 
expresses the overall between-litter variability within a control or dose group. This simplified 
not only the power analysis as only one source for variation had to be considered, the use of 
the CV also meant that the absolute scale of the mean T4 estimate was not relevant for the 
data analysis. 
Prior the power calculations the following questions were investigated: 
• Do the data provide indications for gender differences in the T4 levels? 
• By pooling the serum levels of pups from the same litter, can we expect a smaller 
variability between litter means? (as indication for a more robust litter mean estimate) 
• Which factors influence the litter variability? 
 
Statistical Testing 
As no indications against the assumption of Gaussian distributed effect data were found, 
Analysis of variance (ANOVA) was used to analyze for effects of treatment. Due to the lack 
of homogeneity of variance, the Behrens-Fisher Students' t-test was used always with a 
Satterthwaite approximation for the degrees of freedom.  
 
Data description  
Each individual CV describes the scatter of T4 responses between litters from the same 
control or dose group. The variation of CVs across different studies and dose groups and for 
different age classes is summarized in Table 1. In order to identify CV changes in relation to 
the T4 responses, dose groups were divided into a “low effect” group with mean T4 levels 
above 80% of the controls, and a “high” group with mean T4 levels below 80% of the 
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controls. N refers always to the number of data sets, in case of the controls it equals the 
number of studies.  
As T4 measurements were available only from pups at PND4, the remaining data sets are not 
shown. Here the CVs ranged from 16% to 60%. 
Table 1 shows huge differences between the CVs, in worst cases litter variations with CVs 
above 60% were estimated. Also significant differences between the labs were observed: 
although less data with T4 measurements were provided by DTU, it provides clear 
indications that in average their data variability is much smaller than from other labs.  
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Table 1: Coefficient of variations (CV) for T4 litter samples from dams and pups of various age classes. 
   Dam  Pup       
   GD15 at birth PND0-1 PND3-4 PND7-8 PND14-16 PND21-22 PND27  
DTU Gender           
Control  male N - - - - 1 3 - 1  
  CVrange - - - - 19.4 6.4 [4.3;15.5] - 16.3  
 female N 2 - - - 1 3 - 1  
  CVrange 12.0;12.5 - - - 27 8.9 [7.5;18.5] - 14  
 pooled N - - - 1 1 - - -  
  CVrange - - - 8.2 9.14 - - -  
Low1) male N - - - - - - - -  
  CVrange - - - - - - - -  
 female N 1 - - - - - - -  
  CVrange 12.9 - - - - - - -  
 pooled N - -  3 - -    
  CVrange - -  23.0 
[21.7;34.6] 
- -    
High2) male N - - - - 4 9 - 2  
  CVrange - - - - 18.9 
[15.9;23.1] 
17.4 
[12.2;26.3] 
- 16.8;19.6  
 female N 4 - - - 4 9 - 2  
  CVrange 14.0 
[9.8;20.0] 
- - - 20.6 [7.7;22.9] 12.2 [3.6;38.9] - 10.0;13.8  
 pooled N - - - 3 3 - - -  
  CVrange - - - 6.1 [4.2;7.8] 7.2 [6.8;8.9] - - -  
US-EPA   at birth PND21 PND0-1 PND3-4 PND7-8 PND14-16 PND21-22 >PND36  
Control  pooled N 4 8 3 7 3 11 9 2  
  CVrange 32.3 
[21.4;38.7] 
18.2 
[14.0;26.6] 
18.5 
[15.6;44.8] 
31.4 
[15.3;76.6] 
14.1 
[12.7;29.6] 
13.3 
[11.7;33.1] 
18.1 [8.9;46.1] 17.9;21.1  
Low1) pooled N 3 12 2 11 1 12 10 6  
  CVrange 44.2 
[15.4;68.1] 
26.9 
[14.2;58.1] 
13.6 [9.7;17.6] 29.7 
[18.1;66.6] 
38.4 19.6 
[10.1;39.9] 
16.1 
[10.6;33.5] 
15.2 [11.7;18]  
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High2) pooled N 10 15 4 10 4 19 14 -  
  CVrange 37.8 
[3.5;87.4] 
30.8 
[20.0;71.6] 
40.8 [9.7;52.6] 39.8 
[25.6;80.0] 
33.3 
[26.3;45.3] 
42.8 [0.1;89.5] 38.4 
[14.0;62.8] 
-  
            
N= number of groups, CVrange = median with minimum and maximum (in brackets) 
1) samples from low effect doses (T4 levels >80%); 2) samples from high effect doses (T4 levels <=80%);  
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Gender differences 
Two labs provided measurements from individual pups which allowed the investigation of 
possible gender differences. In these studies T4 levels from only one pup per litter were 
analyzed, and as consequence it was possible to test for gender differences only across litters, 
but not within the same litter. Data from four studies were available, with three providing 
information from more than one developmental age. None of the control groups provided any 
indications for a general gender difference (N=6), neither in terms of statistical significance 
nor of a higher preference of higher (or smaller) values for one gender. However, under 
dosing two samples (out of N=18) yielded different responses: in one study (DTU), two doses 
produced T4 concentrations that were stat. significant higher in male pups (PND27), in the 
other study (data from a different lab, PND4) the opposite was observed, here females 
provided higher measurements at lowest treatment dose (not confirmed at higher doses in the 
same study). In none of the studies a data pooling would have produced different dose-
response results when gender information is ignored. Whether these observed gender 
differences are true or only false-positives cannot be answered with confidence, and more 
empirical evidence is certainly required. Nevertheless, a gender effect cannot completely 
ruled out, and if present (however small), we would expect an increase in data variation 
within the litter if data from the two genders are pooled and used in data analysis. However, 
this does not mean necessarily that the between-litter variability will also increase. If always 
an equal number of male and female pups have been used for the litter mean estimation, 
which is the preferred balanced design approach by US EPA, and more than one pup per sex 
per litter is used, than the precision of the litter mean can be higher than based on only one 
pup. 
To investigate whether the pooling of T4 values from male and female pups (although from 
different litters) could increase the data variability of T4 litter means, CVs were calculated 
for both genders individually and together and then compared. This is illustrated in Figure 1: 
on the x axis the CVs for both genders are shown, and on the y axis the corresponding value 
if both data sets are pooled. The black trend line indicates a perfect 1:1 relationship between 
both CVs, i.e. the case of no gender contribution to the CV, and the red line is the regression 
line together with its 95% CI. Here we included only T4 values from dose groups, i.e. 
controls were excluded from data analysis. The linear regression line agrees well with the 
black reference line, and thus it provides no indications that pooling data from both genders 
will increase the overall variability between litter means. Therefore the factor gender was 
ignored in the power analysis, i.e. we assume that it doesn’t matter whether the litter mean is 
measured from blood samples from one or more individual pups.  
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Figure 1 Variability of T4 measurements from male and female pups (x axis) vs. pooled (y 
axis, expressed by the Coefficient of variation (CV).  
 
CV references for the power analysis 
To identify the best CV candidates for the power analysis, data were further simplified with 
T4 levels from the controls and low effect doses grouped against those from the high effect 
dose, and litter means derived from individual pups were treated in the same way as pooled 
litter means. The results are shown in Table 2.  
To provide more details about the distribution of CV values, data provided by the US EPA 
are shown in Figure 2, separated for dams and pups of different age classes. Each individual 
CV refers to a treatment group (control or exposure), derived from 5 to 28 litters. It should be 
noted that a general trend between litter size and the CV was not identified, i.e. high CVs are 
not due to small sample sizes (however, the precision of an estimated CV decreases with 
increasing sample size). From the graph it can be conclude that 
• data scatter of T4 measurements can vary hugely between different treatment groups 
and studies, 
• it is lower in control and low effect groups than high exposure groups, 
• and the older the pups, the more likely to measure homogenous T4 responses, at least 
in the control and low effect groups.  
Altogether, a reference value well below 20% for the CV must be considered as a rather 
unlikely event. This might be achieved in some labs (see DTU), but not necessarily in all, so 
a CV=20% was regarded as an average expectation. For the worst-case scenario we used a 
CV=30%. 
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Table 2: Coefficient of variations (CV) for T4 litter samples from pups of various age classes. 
  Pup      
DTU  PND0-1 PND3-4 PND7-8 PND14-16 PND21-22 PND27 
T4 reduction 
<20% 
N - 1 2 3 - 1 
CVmedian - 8.2 17.5 7.0 - 14.8 
CV90% 
percentile 
- - 25.8 17.1 -  
T4 reduction 
>=20% 
N - 3 7 9 - 2 
CVmedian - 6.1 11.7 17.7 - 18.6 
 CV90% 
percentile 
- 7.8 21.1 32.2 - 19.8 
member data         
T4 reduction 
<20% 
N - 10 - - - - 
CVmedian - 33.0 - - - - 
 CV90% 
percentile 
- 49.1 - - - - 
T4 reduction 
>=20% 
N - 2 - - - - 
CVmedian - 27.6 - - - - 
 CV90% 
percentile 
- 29.2 - - - - 
US-EPA  PND0-1 PND3-4 PND7-8 PND14-16 PND21-22 >PND36 
T4 reduction 
<20% 
N 5 18 4 23 19 8 
CVmedian 17.6 30.5 21.8 16.0 17.5 17.2 
 CV90% 
percentile 
44.8 66.6 38.4 30.8 33.5 21.1 
T4 reduction 
>=20% 
N 4 10 4 19 14 - 
CVmedian 40.8 39.8 33.3 42.8 38.4 - 
 CV90% 
percentile 
52.6 67.4 45.3 81.7 60.4 - 
        
N= number of data sets 
 
 
Figure 2: Distribution of coefficient of variations (CV) from T4 litter samples. Only data 
from US EPA are shown. Numbers refer to the treatment groups, with controls and low effect 
exposure grouped together.  
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Power and sample size 
As the mean T4 litter values fulfilled the ANOVA assumption of normality, a closed 
mathematical expression exists which determines the exact sample size at given power (or 
vice versa), and therefore it was not necessarily to perform computer-intensive simulation 
studies (DiSantostefano and Muller, 1995). The only requirement for the a priori power 
analysis and corresponding sample size calculation is knowledge about the expected variation 
of the litter means (here always expressed as CV), the T4 change of interest, and the false-
positive rate we are willing to accept. The latter was set to α=5% (two-sided), and a false-
negative rate of maximal β=20% (i.e. power of 80%) was considered as target. In a first step 
the p-value of the t-test was not adjusted for multiple comparison, meaning that the power 
analysis was performed for an individual comparison between control and treatment group. 
As there are various ways to control for the global false-positive rate (see first report), in the 
second step the p value was adjusted by a Bonferroni correction assuming an experimental 
setup of three treatment doses. The Bonferroni correction can be considered as the least 
powerful statistical correction method and is not recommended, as many more powerful 
approaches exists. Nevertheless, the range between the power curves derived from an 
unadjusted and Bonferroni corrected p value indicate the power which can be achieved with 
more advanced statistical approaches to control multiplicity. At given power, therefore both 
curves provide a range of sample sizes (i.e. number of litters) per group which is necessarily 
to identify the T4 change of interest at given error rates and data variability. 
The detection of 20% or 30% changes in control T4 levels were considered of interest, and 
for each we used three different scenarios for the litter means: (i) the variability of the litter 
means in the control and dose group were set to CV=20%, corresponding to an average 
outcome of the previous data analysis (red line), (ii) the variability in the dose group were 
doubled (CV=40%), reflecting more the responses of a high effect dose (blue line), (iii) 
variability in both groups were set to CV=40% (worst-case data scenario) (green line). All 
data analyses were performed by using the statistical software SAS.  
The results are shown in Figure 3 and Figure 4. If the detection a 20% change in the control 
T4 levels at high likelihood is of interest (power > 80%), then at least 17 litter per group are 
required, and if the data variation is above the average, then well above 30 litter are required 
(Figure 3). If the statistical detection limit is lowered to a 30% change, then a sample size of 
10 litters is sufficient assuming average data variability (Figure 4). However, less 
homogenous litter responses will require much higher litter numbers even for this effect size. 
For example, with CVs of 60% the chance of detecting a 50% reduction in T4 levels as 
statistically significant is well below 50% for groups with up to 30 litters. 
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Figure 3: Power to identify a 20 % change in T4 levels at given litter number 
 
 
Figure 4: Power to identify a 30 % change in T4 levels at given litter number 
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APPENDIX 2 
STUDY REPORT FROM DTU FOOD ON MALFORMATIONS OF THE EXTERNAL 
GENITALIA IN YOUNG MALE RAT OFFSPRING 
 
 
This project investigates sexual development in male rat offspring after in utero exposure to the 
endocrine disrupting anti-androgen procymidone. The main purpose of this study was to 
investigate whether malformations of the male offspring’s genitalia could be scored soon after 
birth and furthermore to access weather it was possible to score the degree of these malformations 
early after birth. Moreover whether there is a correlation between anogenital distance (AGD) at 
birth, nipple retention at pup day (PD) 14 and malformations of the external genitalia in the young 
male rat offspring. 
40 paired Wistar rats were dosed with either 0, 25, 50 or 75 mg / kg body weight / day of the 
known anti -androgenic pesticide procymidone from day 7 of gestation to PD 4. At birth the 
following endpoints was recorded: weight of the dams, sex ratio in litters, pup weight and AGD as 
well as external malformations of the sexual organs. A score of 0-3 was used for the external 
malformations. Score 0 indicated normal while score 3 indicated very severe malformations. All 
male rats were kept until PD 55. All male offspring were examined for external abnormalities of 
the genitals at PD 6, PD 14, PD 22 and PD 54 /55. In addition, the animals were tested for nipple 
retention at UD 14, and their penile length was measured at UD 55. 
The study showed that AGD was significantly decreased in all exposed groups (p <0.01) and that 
the males from all exposed groups showed a significant increase in the malformation score 
compared with the control males ( at both UD 6, UD 14, UD 22 and UD 54 /55 ) . There was an 
increase in the number of males with malformations from day 0 to day 6, and a dose-related 
correlation between reduced AGD and the increased occurrence of malformations. This reduction 
was more evident on days 6, 14 and 22 than on day 0. On day 54-55 , where the male rats were 
sexually mature , also cryptorchidism were seen as well as  a dose - related decrease in penis 
length . 
The results support that a change in AGD may predict permanent malformations of the external 
genitalia in rats later in life. Anogenital distance seems to be a reliable biomarker for later 
malformations and decreased penile length. Malformations of male offspring’s genitalia could be 
scored early after birth (day 0 and day 6 in particular) and these early abnormalities turned out to 
be permanent and seemed to be deteriorating/worsening with age. 
 
Results are seen below (unpublished) 
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